The Board of Directors of MolMed S.p.A. (MLM.MI), chaired by Prof. Claudio Bordignon, today reviewed and approved the interim financial report at 31 March 2013. The most important elements were:
- progress on dossier preparation to file a market...
More
The Board of Directors of MolMed S.p.A. (MLM.MI), chaired by Prof. Claudio Bordignon, today reviewed and approved the interim financial report at 31 March 2013. The most important elements were:
- progress on dossier preparation to file a market authorisation application for TK through the Conditional Marketing Authorisation procedure with the European Medicines Agency;
- continuation of ongoing clinical trials both for TK and NGR-hTNF.
Key achievements in the first three months of 2013
Research & Clinical Development activities
In the first three months of 2013, the Company’s activities were mainly focused on the clinical development of its two investigational anticancer therapeutics: TK for the treatment of high-risk leukaemia and NGR-hTNF for the treatment of a panel of solid tumours.
With regard to TK, main progress achieved during the first quarter 2013 include:
- progress on dossier preparation to file a market authorisation application for TK through a specific pr
Less
